Posts for Ticker ‘ALNY’

Biotech Business Daily (BIIB, VRTX, ALNY, STEM)

Here are some of the top stories affecting key drug and biotech stocks this Friday.  We also have links through to more detailed coverage and analysis at BioHealthInvestor.com:

Biogen Idec Inc. (Nasdaq: BIIB) kicks off the earnings season for the large biotech companies next week. We have a full earnings preview with current expectations and the bias.  A decline in analyst sentiment for the stock might set up the company for a slight earnings surprise, on the back of recent price increases for its high-profile multiple sclerosis drug Avonex.

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) this morning said it will sell its rights to milestone payments tied to its hepatitis C drug telaprevir in Europe, a possible sign that the launch of the drug with partner Johnson & Johnson (NYSE: JNJ) for 2011 may be on track.

Also, see our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 10, 2009 – 10:07 am in Biotech, , , ,

Biotech Business Daily (RIGL, BIIB, ARRY, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth coverage and analysis today at the website BioHealthInvestor.com:

Rigel Pharmaceuticals Inc.’s (NASDAQ: RIGL) Phase IIb trial results Thursday morning of its rheumatoid arthritis candidate R788, is boosting its stock on speculation it may help the company attract a clinical partner.

Biogen Idec Inc. (NASDAQ: BIIB) is enjoying a second day of gains after its new PEGylated interferon beta-1a (BIIB017) for relapsing multiple sclerosis (RMS) received an FDA Fast Track designation.  This might be a game-changing event for the company with some risks as well.

Array BioPharma Inc. (Nasdaq: ARRY) now says it will discontinue development of ARRY-797 in chronic inflammatory diseases. Attention may now turn to Array’s ARRY-162, another anti-inflammatory that showed much more promising efficacy.

Also, see our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 9, 2009 – 11:09 am in Biotech, Drug companies, FDA, Medical, , , , , , , ,

BioHealth Business Daily (CI, AET, MYL, JAZZ, PTIE, GSK, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that are covered in-depth today at BioHealthInvestor.com:

Cigna corp. (NYSE: CI), Aetna Inc. (NYSE: AET), and other managed care companies are rising despite making health care reform concessions, as shareholders see they have a seat at the bargaining table.

Mylan Inc. (NASDAQ: MYL) has received FDA approval for a generic version of an AstraZeneca (AZN) prostate cancer drug — a rather unusual new generic.

Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) shares are up more than 25 percent after the company took steps to ease a cash crunch that had curtailed drug development.

King Pharmaceuticals (KG) and Pain Therapeutics (PTIE) said  they expect to resubmit a new drug application in mid-2010, slightly later than anticipated.

GlaxoSmithKline (NYSE: GSK) announced a positive study on its Cervarix vaccine, although it’s unclear if the company can play catch-up to Merck & Co.’s (NYSE: MRK) Gardasil.

See our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 7, 2009 – 11:03 am in Biotech, Drug companies, FDA, Medical, Trading Alert, , , , , , , , , , ,

The Five Growth Biotech Names To Watch Right Now

biotechAlnylam (Nasdaq: ALNY) leads a short list of some of the fastest-growing biotech stocks
where analyst estimate revisions continue to rise.

BioHealth Investor began by analyzing 171 stocks in the biotech sector based on revenue growth over the trailing four quarters, identifying 30 stocks in the sector with better
than 50 percent revenue growth over the past 12 months.

We then screened those 30 stocks to look for those very few names that have seen both strong growth in at least the past two years and positive analyst estimate revisions in recent months, in an effort to find stocks with strong trends that still have potentially improving operations going forward.

The work resulted in growth biotech stocks to watch: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM). Read More »

Posted on: July 6, 2009 – 4:27 am in Biotech, , , , ,

Top Analyst Upgrades (ALNY, DB, DSCM, ZEUS, SEPR, X, YHOO)

These are some of the top pre-market analyst upgrades and positive research calls we have seen from Wall Street research calls early this Wednesday morning:

Alnylam (ALNY) Started as Buy at Jefferies and at Roth.
Deutsche Bank (DB) Raised to Neutral at JPMorgan.
Drugstore.com (DDSCM) Started as Buy at Janney Montgomey Scott.
Olympic Steel (ZEUS) Raised to Buy at KeyBanc.
Sepracor (SEPR) Started as Buy at Sun Trust Robinson Humphrey.
US Steel (X) Raised to Buy at KeyBanc.
Yahoo! (YHOO) Raised to Buy at Soleil.

JON C. OGG

Posted on: June 10, 2009 – 6:58 am in Analyst Calls, , , , , , ,

Early-Bird Analyst Downgrades (AAP, ALNY, COMV, DISH, DPS, HAS, NATI, NVTL, STEL)

These are some of the early analyst downgrades or negative calls we are seeing this Wednesday in early pre-market hours:

  • Advance Auto Parts (AAP) Cut to Neutral at JPMorgan.
  • Alnylam Pharma (ALNY) Started as Underperform at Leerink Swann.
  • Comverge (COMV) Cut to Neutral at Broadpoint Capital.
  • DISH Network (DISH) Cut to Market Perform at Bernstein.
  • Dr. Pepper Snapple (DPS) Cut to Neutral at UBS.
  • Hasbro (HAS) Cut to Underperform at BMO Capital.
  • National Instruments (NATI) Cut to Neutral at Credit Suisse.
  • Novatel Wireless (NVTL) Cut to Sell at Piper Jaffray.
  • StellarOne (STEL) Cut to Underperform at Baird.

JON C. OGG
August 20, 2008

Posted on: August 20, 2008 – 6:32 am in Analyst Calls, , , , , , , , ,

Alnylam Cancels Conference… What’s Brewing? (ALNY)

Alnylam_logoWe just saw a report out of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) that may get traders moving on both sides of the stock.  The company has just announced that management will not be presenting at the Bank of America 2008 Specialty Pharmaceuticals Conference on August 8, 2008, as previously scheduled. The company’s planned update on its scientific platform and delivery approaches will be presented at another investor conference in the near future.

Read More »

Posted on: August 4, 2008 – 4:15 pm in Biotech,

Today in Biotech Stocks (ALNY, ARIA, CEPH, CYPB, GTCB, ITMN)

Below are some of the news items affecting shares of biotech stocks:

  • Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is enjoying upgrades after a positive earnings release Thursday. The company’s partnership with Swiss drug maker Roche on RNA-interference drugs drove its fourth quarter profit. RNA-interface drugs work by turning off genes that cause illnesses. The prospect of more deals and partnerships in the future is driving up the stock, up over 7% at mid-day to $32.61. The 52 week range is $14.87 to $37.35.
  • Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) down almost 6% at mid-day despite improved financial results and positive guidance. The stock is trading at $3.14 at mid-day on thin trading volume.
  • Cephalon Inc. (NASDAQ: CEPH) paid lobbyist group Capitol Decisions $80,000 to push their drug for alcoholism, Vivitrol. Along with a downgrade and resignation of executive VP, John Osborn, the stock is down 7% to $59.08 at mid-day, a new 52 week low. The 52 week range is $62.93 to $84.83.
  • Business Week’s "Inside Wall Street" has a note today on Cypress Bioscience (NASDAQ: CYPB) showing hedge fund interest based upon the future of its treatment for fibromyalgia that is in Phase III studies.  It lists the drug candidate as having $1 billion potential sales, or the blockbuster drug category, although shares are essentially flat today at $8.38.
  • GTC Biotherapeutics Inc. (NASDAQ: GTCB) announced plans to raise $6 million to fund day-to-day operations by issuing new stock at $0.87 per share. Their lead drug, ATryn, an anti-clotting drug, is currently in clinical trials. Shares down at $0.76 mid-day.
  • InterMune, Inc. (NASDAQ: ITMN) was down over 3% at mid-day to $15.81 after fourth quarter losses.

This week we also noted how many of the stocks that are involved in stem cell research may be the winners of this week’s Super Tuesday presidential primaries over the long haul.

Rachel Lopez
February 8, 2008

Posted on: February 8, 2008 – 12:32 pm in Biotech, , , , , ,

Alnylam Pharmaceuticals (ALNY): A Big Break

Alnylam Pharmaceuticals (ALNY), an RNAi therapeutics company, has signed a huge license with Roche which could be worth as much as $1 billion The small company had total revenue fo $26 million last year.

Under the terms of the agreeement: "Alnylam will give Roche a non-exclusive license to its technology. Roche will pay $331 million in upfront fees, including making an investment of just under 2 million shares of Alnylam stock, representing nearly 5 percent of the company’s outstanding shares," according to the AP.

Shares in ALNY are up 52% to $23.30, which takes the company’s market cap to $875 million.

The stock still looks cheap.

Douglas A. McIntyre

Posted on: July 9, 2007 – 8:39 am in Uncategorized,